KR102417127B1 - 대형 유전자 절제 및 삽입 - Google Patents

대형 유전자 절제 및 삽입 Download PDF

Info

Publication number
KR102417127B1
KR102417127B1 KR1020167015896A KR20167015896A KR102417127B1 KR 102417127 B1 KR102417127 B1 KR 102417127B1 KR 1020167015896 A KR1020167015896 A KR 1020167015896A KR 20167015896 A KR20167015896 A KR 20167015896A KR 102417127 B1 KR102417127 B1 KR 102417127B1
Authority
KR
South Korea
Prior art keywords
nucleic acid
base pairs
acid sequence
dna
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167015896A
Other languages
English (en)
Korean (ko)
Other versions
KR20160078502A (ko
Inventor
수산 엠. 바이른
조지 엠. 처치
Original Assignee
프레지던트 앤드 펠로우즈 오브 하바드 칼리지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53173682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102417127(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 filed Critical 프레지던트 앤드 펠로우즈 오브 하바드 칼리지
Priority to KR1020227022535A priority Critical patent/KR20220100090A/ko
Publication of KR20160078502A publication Critical patent/KR20160078502A/ko
Application granted granted Critical
Publication of KR102417127B1 publication Critical patent/KR102417127B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020167015896A 2013-11-19 2014-11-19 대형 유전자 절제 및 삽입 Active KR102417127B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227022535A KR20220100090A (ko) 2013-11-19 2014-11-19 대형 유전자 절제 및 삽입

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361906188P 2013-11-19 2013-11-19
US61/906,188 2013-11-19
PCT/US2014/066324 WO2015077290A2 (en) 2013-11-19 2014-11-19 Large gene excision and insertion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227022535A Division KR20220100090A (ko) 2013-11-19 2014-11-19 대형 유전자 절제 및 삽입

Publications (2)

Publication Number Publication Date
KR20160078502A KR20160078502A (ko) 2016-07-04
KR102417127B1 true KR102417127B1 (ko) 2022-07-05

Family

ID=53173682

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167015896A Active KR102417127B1 (ko) 2013-11-19 2014-11-19 대형 유전자 절제 및 삽입
KR1020247020768A Pending KR20240104191A (ko) 2013-11-19 2014-11-19 대형 유전자 절제 및 삽입
KR1020227022535A Ceased KR20220100090A (ko) 2013-11-19 2014-11-19 대형 유전자 절제 및 삽입

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247020768A Pending KR20240104191A (ko) 2013-11-19 2014-11-19 대형 유전자 절제 및 삽입
KR1020227022535A Ceased KR20220100090A (ko) 2013-11-19 2014-11-19 대형 유전자 절제 및 삽입

Country Status (9)

Country Link
US (2) US10787684B2 (enExample)
EP (3) EP3604543A1 (enExample)
JP (2) JP7066956B2 (enExample)
KR (3) KR102417127B1 (enExample)
AU (3) AU2014353100B2 (enExample)
CA (1) CA2930828C (enExample)
DK (1) DK3071698T3 (enExample)
ES (1) ES2754498T3 (enExample)
WO (1) WO2015077290A2 (enExample)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
PL4289948T3 (pl) 2012-05-25 2025-06-02 The Regents Of The University Of California Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji
EP4282970A3 (en) * 2012-12-17 2024-01-17 President and Fellows of Harvard College Rna-guided human genome engineering
CA2908697C (en) 2013-04-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US10584358B2 (en) 2013-10-30 2020-03-10 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
JP2016536021A (ja) 2013-11-07 2016-11-24 エディタス・メディシン，インコーポレイテッド ＣＲＩＳＰＲ関連方法および支配ｇＲＮＡのある組成物
SG10201700961TA (en) 2013-12-11 2017-04-27 Regeneron Pharma Methods and compositions for the targeted modification of a genome
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
EP3957735A1 (en) 2014-03-05 2022-02-23 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
ES2745769T3 (es) 2014-03-10 2020-03-03 Editas Medicine Inc Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10)
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
WO2015148863A2 (en) 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
US12460231B2 (en) 2014-04-02 2025-11-04 Editas Medicine, Inc. Crispr/CAS-related methods and compositions for treating primary open angle glaucoma
WO2015155686A2 (en) 2014-04-08 2015-10-15 North Carolina State University Methods and compositions for rna-directed repression of transcription using crispr-associated genes
BR122023023211A2 (pt) 2014-04-28 2024-01-23 Recombinetics, Inc. Método de fazer edições de genes multiplex em uma célula de vertebrado ou de embrião primário não-humano
HUE049776T2 (hu) 2014-06-06 2020-10-28 Regeneron Pharma Módszerek és készítmények egy célzott lókusz módosítására
EP3161128B1 (en) 2014-06-26 2018-09-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10450584B2 (en) 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
DK3207124T3 (da) 2014-10-15 2019-08-12 Regeneron Pharma Fremgangsmåder og sammensætninger til generering eller bevaring af pluripotente celler
US11680268B2 (en) 2014-11-07 2023-06-20 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
EP3221457B1 (en) 2014-11-21 2019-03-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
US10900034B2 (en) 2014-12-03 2021-01-26 Agilent Technologies, Inc. Guide RNA with chemical modifications
CN113699116A (zh) 2014-12-10 2021-11-26 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
JP6840077B2 (ja) 2014-12-19 2021-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物
CN105821073B (zh) 2015-01-27 2021-08-10 中国科学院遗传与发育生物学研究所 一种通过基因瞬时表达对整株植物定点改造的方法
KR102888521B1 (ko) 2015-04-06 2025-11-19 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
EP4019975A1 (en) 2015-04-24 2022-06-29 Editas Medicine, Inc. Evaluation of cas9 molecule/guide rna molecule complexes
EP3095870A1 (en) 2015-05-19 2016-11-23 Kws Saat Se Methods for the in planta transformation of plants and manufacturing processes and products based and obtainable therefrom
AU2016270649B2 (en) 2015-05-29 2022-04-21 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
MX2017015582A (es) 2015-06-01 2018-09-06 Univ Temple Metodos y composiciones para tratamiento guiado por arn de infeccion por vih.
ES2960226T3 (es) 2015-06-15 2024-03-01 Univ North Carolina State Métodos y composiciones para la administración eficiente de ácidos nucleicos y antimicrobianos basados en ARN
IL295616A (en) 2015-07-31 2022-10-01 Us Health Adapted cells and treatment methods
EP3334832A4 (en) * 2015-08-14 2019-06-26 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences PROCESS FOR THE PREPARATION OF GLYPHOSATE-RESISTANT RICE BY TARGETED NUCLEOTIDE SUBSTITUTION
EP3786294A1 (en) 2015-09-24 2021-03-03 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
EP4434589A3 (en) 2015-10-23 2025-05-14 President and Fellows of Harvard College Evolved cas9 proteins for gene editing
JP2018532415A (ja) * 2015-11-06 2018-11-08 ザ ジャクソン ラボラトリー 大きなゲノムｄｎａノックインおよびその使用
WO2017112620A1 (en) 2015-12-22 2017-06-29 North Carolina State University Methods and compositions for delivery of crispr based antimicrobials
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
WO2017165862A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
WO2017180694A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Cas9 fusion molecules gene editing systems, and methods of use thereof
CN105861485B (zh) * 2016-04-20 2021-08-17 上海伊丽萨生物科技有限公司 一种提高基因置换效率的方法
CN109475109B (zh) 2016-05-20 2021-10-29 瑞泽恩制药公司 用于使用多个引导rna来破坏免疫耐受性的方法
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
US11174469B2 (en) 2016-06-29 2021-11-16 Crispr Therapeutics Ag Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
US20190153430A1 (en) * 2016-08-02 2019-05-23 Kyoto University Method for genome editing
CA3032822A1 (en) 2016-08-02 2018-02-08 Editas Medicine, Inc. Compositions and methods for treating cep290 associated disease
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
CN109963945A (zh) * 2016-08-20 2019-07-02 阿维利诺美国实验室股份有限公司 单一向导rna、crispr/cas9系统及其使用方法
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
EP4338799A3 (en) 2016-10-18 2024-06-05 Regents of the University of Minnesota Tumor infiltrating lymphocytes and methods of therapy
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US12058986B2 (en) 2017-04-20 2024-08-13 Egenesis, Inc. Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements
WO2018209158A2 (en) 2017-05-10 2018-11-15 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
MX2019015188A (es) * 2017-06-15 2020-08-03 Univ California Inserciones de adn no virales orientadas.
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
JP2020534812A (ja) * 2017-09-08 2020-12-03 ライフ テクノロジーズ コーポレイション 改良された相同組換えおよびその組成物のための方法
KR20200121782A (ko) 2017-10-16 2020-10-26 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
WO2019093418A1 (ja) * 2017-11-13 2019-05-16 国立大学法人広島大学 哺乳動物細胞内の標的染色体部位で目的遺伝子を含むポリヌクレオチドを増幅させる方法およびベクター、ならびにその利用
US20200370070A1 (en) * 2017-11-17 2020-11-26 The Johns Hopkins University Compositions and methods for efficient genome editing
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3765614A1 (en) 2018-03-14 2021-01-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
US20210180045A1 (en) * 2018-08-31 2021-06-17 The Children's Hospital Of Philadelphia Scalable tagging of endogenous genes by homology-independent intron targeting
WO2020072253A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for screening for variant cells
WO2020072248A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system
US12264330B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
US12264313B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for genome modification and alteration of expression
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
US20220186263A1 (en) * 2019-04-05 2022-06-16 Osaka University Method for producing knock-in cell
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
EP4085145A4 (en) * 2019-12-30 2024-02-21 The Broad Institute Inc. Guided excision-transposition systems
JP6867635B1 (ja) * 2020-04-06 2021-04-28 株式会社Logomix ゲノム改変方法及びゲノム改変キット
KR20220164748A (ko) * 2020-04-06 2022-12-13 가부시키가이샤 로고믹스 게놈 개변 방법 및 게놈 개변 키트
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11760989B2 (en) 2020-06-06 2023-09-19 Lanzatech, Inc. Microorganism with knock-in at acetolactate decarboxylase gene locus
US20240424035A1 (en) * 2021-01-26 2024-12-26 Washington State University Bacteria producing gamma-aminobutyric acid (gaba) and uses of the bacteria
WO2023039586A1 (en) 2021-09-10 2023-03-16 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
KR20240099259A (ko) 2021-10-14 2024-06-28 아스널 바이오사이언시스, 인크. 공동 발현된 shrna 및 논리 게이트 시스템을 갖는 면역 세포
WO2023077148A1 (en) 2021-11-01 2023-05-04 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
AU2022420615A1 (en) 2021-12-22 2024-07-04 Tome Biosciences, Inc. Co-delivery of a gene editor construct and a donor template
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
CN114891750A (zh) * 2022-04-29 2022-08-12 武汉大学 筛选经cyp3a4介导代谢毒性外源化合物的细胞模型及其构建方法、应用
TWI840799B (zh) * 2022-05-02 2024-05-01 國立臺灣海洋大學 水產生物及水產品之外源性分子追溯方法及其系統
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
WO2024138194A1 (en) 2022-12-22 2024-06-27 Tome Biosciences, Inc. Platforms, compositions, and methods for in vivo programmable gene insertion
WO2024234006A1 (en) 2023-05-11 2024-11-14 Tome Biosciences, Inc. Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
WO2025050069A1 (en) 2023-09-01 2025-03-06 Tome Biosciences, Inc. Programmable gene insertion using engineered integration enzymes
WO2025224107A1 (en) 2024-04-22 2025-10-30 Basecamp Research Ltd Method and compositions for detecting off-target editing
WO2025224182A2 (en) 2024-04-23 2025-10-30 Basecamp Research Ltd Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2719789T3 (es) 2007-03-02 2019-07-16 Dupont Nutrition Biosci Aps Cultivos con resistencia mejorada a fagos
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
US20120315670A1 (en) 2009-11-02 2012-12-13 Gen9, Inc. Compositions and Methods for the Regulation of Multiple Genes of Interest in a Cell
US10087431B2 (en) 2010-03-10 2018-10-02 The Regents Of The University Of California Methods of generating nucleic acid fragments
BR112012028805A2 (pt) 2010-05-10 2019-09-24 The Regents Of The Univ Of California E Nereus Pharmaceuticals Inc composições de endorribonuclease e métodos de uso das mesmas.
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
CN104284669A (zh) 2012-02-24 2015-01-14 弗雷德哈钦森癌症研究中心 治疗血红蛋白病的组合物和方法
NZ629427A (en) 2012-02-29 2016-04-29 Sangamo Biosciences Inc Methods and compositions for treating huntington’s disease
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
CN104364380B (zh) 2012-04-25 2018-10-09 瑞泽恩制药公司 核酸酶介导的使用大靶向载体的靶向
CA2871524C (en) 2012-05-07 2021-07-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
PL4289948T3 (pl) 2012-05-25 2025-06-02 The Regents Of The University Of California Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji
WO2014022702A2 (en) 2012-08-03 2014-02-06 The Regents Of The University Of California Methods and compositions for controlling gene expression by rna processing
EP2912175B1 (en) * 2012-10-23 2018-08-22 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014093622A2 (en) * 2012-12-12 2014-06-19 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
EP4282970A3 (en) * 2012-12-17 2024-01-17 President and Fellows of Harvard College Rna-guided human genome engineering
JP2016522679A (ja) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
US20140359795A1 (en) * 2013-05-31 2014-12-04 Recombinetics, Inc. Genetic techniques for making animals with sortable sperm
US20140356956A1 (en) * 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
EP3418379B1 (en) * 2013-09-18 2020-12-09 Kymab Limited Methods, cells & organisms
SG10201700961TA (en) 2013-12-11 2017-04-27 Regeneron Pharma Methods and compositions for the targeted modification of a genome

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biochemical and Biophysical Research Communications. 2013, 441:815-819. Available Online 6 November 2013.*
Genetics. August 2013, 194:1029-1035.*

Also Published As

Publication number Publication date
JP2016537982A (ja) 2016-12-08
US20150140664A1 (en) 2015-05-21
DK3071698T3 (da) 2019-11-18
JP7066956B2 (ja) 2022-05-16
EP3071698A2 (en) 2016-09-28
AU2021201624A1 (en) 2021-04-08
CA2930828A1 (en) 2015-05-28
AU2021201624B2 (en) 2024-02-08
US20210147879A1 (en) 2021-05-20
AU2024203000A1 (en) 2024-05-30
KR20240104191A (ko) 2024-07-04
EP4560022A2 (en) 2025-05-28
KR20220100090A (ko) 2022-07-14
JP2020062033A (ja) 2020-04-23
WO2015077290A2 (en) 2015-05-28
KR20160078502A (ko) 2016-07-04
AU2014353100B2 (en) 2020-12-17
CA2930828C (en) 2022-05-03
WO2015077290A3 (en) 2015-08-06
ES2754498T3 (es) 2020-04-17
EP4560022A3 (en) 2025-08-20
EP3071698B1 (en) 2019-09-04
JP7036512B2 (ja) 2022-03-15
EP3071698A4 (en) 2017-06-28
US10787684B2 (en) 2020-09-29
AU2014353100A1 (en) 2016-06-02
EP3604543A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
KR102417127B1 (ko) 대형 유전자 절제 및 삽입
EP3708671B1 (en) Methods and compositions for modifying a targeted locus
WO2015013583A2 (en) Genome engineering
US11499164B2 (en) Methods for scarless introduction of targeted modifications into targeting vectors
EP4242237A1 (en) Foki nuclease domain variant
HK40023048A (en) Large gene excision and insertion
RU2812848C2 (ru) Геномная инженерия
HK1229380B (en) Large gene excision and insertion
HK1229380A1 (en) Large gene excision and insertion
HK40043169B (en) Methods for scarless introduction of targeted modifications into targeting vectors
HK40043169A (en) Methods for scarless introduction of targeted modifications into targeting vectors
HK1235817A1 (en) Methods and compositions for modifying a targeted locus

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160615

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190315

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200914

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210116

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200914

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210116

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20201116

Comment text: Amendment to Specification, etc.

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20210504

Patent event code: PE09021S02D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20220330

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20211104

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210419

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210116

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20201116

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220630

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220630

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220701

End annual number: 3

Start annual number: 1

PG1601 Publication of registration